Baidu
map

Neurology:哪些情况下叶酸预防卒中的效果更佳?

2017-06-01 吴星 环球医学

2017年5月,《Neurology》发表了一项叶酸预防卒中的有效性的荟萃分析。目的:基于相关、最新发表的随机试验,考察在没有叶酸强化的地区,补充叶酸预防卒中的有效性和影响因素。方法:在固定效应模型中,使用相对风险(RR)测量叶酸补充剂对卒中风险的影响。结果:总体而言,叶酸补充剂显着降低11%的卒中风险(22项试验,n=82723;RR 0.89,95% 置信区间[CI] 0.84~0.96)。与

2017年5月,《Neurology》发表了一项叶酸预防卒中的有效性的荟萃分析。

目的:基于相关、最新发表的随机试验,考察在没有叶酸强化的地区,补充叶酸预防卒中的有效性和影响因素。

方法:在固定效应模型中,使用相对风险(RR)测量叶酸补充剂对卒中风险的影响。

结果:总体而言,叶酸补充剂显着降低11%的卒中风险(22项试验,n=82723;RR 0.89,95% 置信区间[CI] 0.84~0.96)。与高叶酸地区相比(7项试验,n=14655;美洲,1.05,0.90~1.23),叶酸补充对低叶酸地区影响更大(2项试验,n=24020;亚洲,0.78,0.67~0.90)。与有叶酸强化的地区(7项试验,n=14655;1.05,0.90~1.23)相比,叶酸补充对无叶酸强化的地区影响更大(11项试验,n=49957;0.85;0.77~0.94)。对无叶酸强化的试验进一步分层分析,使用低剂量叶酸(≤0.8 mg:0.78,0.69~0.88)或基线维生素B12水平低(<384 pg/mL:0.78,0.68~0.89)的试验获益效果更大。在相应的比较组重,效应量减弱且不显着(二者相互作用p<0.05)。尽管相互作用测试不显着,但在低剂量维生素B12、他汀使用率低但高血压率高的试验中可能有更高的获益。

结论:补充叶酸能降低无叶酸强化地区的卒中风险,尤其在使用相对低剂量叶酸和患者低维生素B12水平的试验中。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1999959, encodeId=1c071999959c3, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Dec 11 15:35:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205461, encodeId=b91e2054619c, content=叶酸, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=445f1740270, createdName=meiliwuxian, createdTime=Fri Jun 02 06:39:44 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205287, encodeId=6a9b20528ef1, content=学习了,很好,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Thu Jun 01 17:05:58 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205282, encodeId=5a24205282aa, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Thu Jun 01 16:51:05 CST 2017, time=2017-06-01, status=1, ipAttribution=)]
    2017-12-11 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=1999959, encodeId=1c071999959c3, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Dec 11 15:35:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205461, encodeId=b91e2054619c, content=叶酸, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=445f1740270, createdName=meiliwuxian, createdTime=Fri Jun 02 06:39:44 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205287, encodeId=6a9b20528ef1, content=学习了,很好,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Thu Jun 01 17:05:58 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205282, encodeId=5a24205282aa, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Thu Jun 01 16:51:05 CST 2017, time=2017-06-01, status=1, ipAttribution=)]
    2017-06-02 meiliwuxian

    叶酸

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1999959, encodeId=1c071999959c3, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Dec 11 15:35:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205461, encodeId=b91e2054619c, content=叶酸, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=445f1740270, createdName=meiliwuxian, createdTime=Fri Jun 02 06:39:44 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205287, encodeId=6a9b20528ef1, content=学习了,很好,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Thu Jun 01 17:05:58 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205282, encodeId=5a24205282aa, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Thu Jun 01 16:51:05 CST 2017, time=2017-06-01, status=1, ipAttribution=)]
    2017-06-01 dhzzm

    学习了,很好,值得关注

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1999959, encodeId=1c071999959c3, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Dec 11 15:35:00 CST 2017, time=2017-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205461, encodeId=b91e2054619c, content=叶酸, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=445f1740270, createdName=meiliwuxian, createdTime=Fri Jun 02 06:39:44 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205287, encodeId=6a9b20528ef1, content=学习了,很好,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Thu Jun 01 17:05:58 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205282, encodeId=5a24205282aa, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Thu Jun 01 16:51:05 CST 2017, time=2017-06-01, status=1, ipAttribution=)]
    2017-06-01 天涯183

    非常好的文章,学习了,很受益

    0

相关资讯

Stroke:精神疾病住院增加了卒中短期风险!

由此可见,因精神疾病住院增加了卒中的短期风险,尤其是住院后15天内。

BMJ:哪些急性缺血性卒中患者可行动脉内治疗获益?临床决策工具告诉你

卒中是全世界第二大常见死亡原因,以及高收入国家中最常见的致残因素。2017年5月,《BMJ》上发表了急性缺血性卒中患者动脉内治疗的选择:两项随机试验中临床决策工具的开发和验证。

Neurology:2002-2013年卒中及其危险因素的流行病学分析!

在2002年至2013年,在中国脑卒中的发病率迅速上升。结合高患病率,具有年轻化的趋势,并且死亡率稳定,这一发现表明对代谢和生活方式的危险因素进行额外的临床和行为干预在预防卒中上是必要的,特别是在某些人群中。

Stroke:24小时血压变异性与收缩压对卒中溶栓结局的交互作用分析!

该研究表明在BP治疗前和急性BP变化过程中(即,BPV)需要更加个性化的血压管理,以使患者达到最好的可能结局。

Neurology:卒中或TIA幸存者的长期未满足需求及相关因素分析!

脑卒中或TIA幸存者出院后超过2年的未满足需求相当大,特别是在二级预防领域。与未满足需求相关的因素可能有助于指导决策,特别是出院后个体化护理和提供的支持服务。

Neurology:氯吡格雷-阿司匹林治疗小卒中或TIA的风险和获益

2017年5月,发表在《Neurology》上的CHANCE试验的分析,考察了氯吡格雷-阿司匹林治疗小卒中或TIA的风险和获益。目的:考察氯吡格雷联合阿司匹林治疗缺血性小卒中或TIA的短期风险和获益。方法:从急性非致残性脑血管事件高风险患者使用氯吡格雷(Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular

Baidu
map
Baidu
map
Baidu
map